BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 23155147)

  • 1. Carbapenem-sparing antibiotic regimens for infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae in intensive care unit.
    Sbrana F; Malacarne P; Viaggi B; Costanzo S; Leonetti P; Leonildi A; Casini B; Tascini C; Menichetti F
    Clin Infect Dis; 2013 Mar; 56(5):697-700. PubMed ID: 23155147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical issues for Klebsiella pneumoniae KPC-carbapenemase producing K. pneumoniae infections: a critical agenda.
    De Rosa FG; Corcione S; Cavallo R; Di Perri G; Bassetti M
    Future Microbiol; 2015; 10(2):283-94. PubMed ID: 25689539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carbapenem-resistant Klebsiella pneumoniae endocarditis in a young adult. Successful treatment with gentamicin and colistin.
    Benenson S; Navon-Venezia S; Carmeli Y; Adler A; Strahilevitz J; Moses AE; Block C
    Int J Infect Dis; 2009 Sep; 13(5):e295-8. PubMed ID: 19329345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria.
    Pontikis K; Karaiskos I; Bastani S; Dimopoulos G; Kalogirou M; Katsiari M; Oikonomou A; Poulakou G; Roilides E; Giamarellou H
    Int J Antimicrob Agents; 2014 Jan; 43(1):52-9. PubMed ID: 24183799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple combination antibiotic therapy for carbapenemase-producing Klebsiella pneumoniae: a systematic review.
    Jacobs DM; Safir MC; Huang D; Minhaj F; Parker A; Rao GG
    Ann Clin Microbiol Antimicrob; 2017 Nov; 16(1):76. PubMed ID: 29178957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An outbreak of infection due to beta-Lactamase Klebsiella pneumoniae Carbapenemase 2-producing K. pneumoniae in a Greek University Hospital: molecular characterization, epidemiology, and outcomes.
    Souli M; Galani I; Antoniadou A; Papadomichelakis E; Poulakou G; Panagea T; Vourli S; Zerva L; Armaganidis A; Kanellakopoulou K; Giamarellou H
    Clin Infect Dis; 2010 Feb; 50(3):364-73. PubMed ID: 20041768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae in solid organ transplantation.
    Bergamasco MD; Barroso Barbosa M; de Oliveira Garcia D; Cipullo R; Moreira JC; Baia C; Barbosa V; Abboud CS
    Transpl Infect Dis; 2012 Apr; 14(2):198-205. PubMed ID: 22093103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful Treatment of Carbapenemase-Producing Pandrug-Resistant Klebsiella pneumoniae Bacteremia.
    Camargo JF; Simkins J; Beduschi T; Tekin A; Aragon L; Pérez-Cardona A; Prado CE; Morris MI; Abbo LM; Cantón R
    Antimicrob Agents Chemother; 2015 Oct; 59(10):5903-8. PubMed ID: 26386029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mortality Associated with Bacteremia Due to Colistin-Resistant Klebsiella pneumoniae with High-Level Meropenem Resistance: Importance of Combination Therapy without Colistin and Carbapenems.
    Machuca I; Gutiérrez-Gutiérrez B; Gracia-Ahufinger I; Rivera Espinar F; Cano Á; Guzmán-Puche J; Pérez-Nadales E; Natera C; Rodríguez M; León R; Castón JJ; Rodríguez-López F; Rodríguez-Baño J; Torre-Cisneros J
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergence of tigecycline- and carbapenem-nonsusceptible Klebsiella pneumoniae ST11 clone in patients without exposure to tigecycline.
    Sheng ZK; Wang W; Guo Q; Xu X; Wang M; Yang Y; Wang M
    J Microbiol Immunol Infect; 2016 Dec; 49(6):962-968. PubMed ID: 26692183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic strategy for pandrug-resistant Klebsiella pneumoniae severe infections: short-course treatment with colistin increases the in vivo and in vitro activity of double carbapenem regimen.
    Oliva A; Mascellino MT; Cipolla A; D'Abramo A; De Rosa A; Savinelli S; Ciardi MR; Mastroianni CM; Vullo V
    Int J Infect Dis; 2015 Apr; 33():132-4. PubMed ID: 25597275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gentamicin therapy for sepsis due to carbapenem-resistant and colistin-resistant Klebsiella pneumoniae.
    Gonzalez-Padilla M; Torre-Cisneros J; Rivera-Espinar F; Pontes-Moreno A; López-Cerero L; Pascual A; Natera C; Rodríguez M; Salcedo I; Rodríguez-López F; Rivero A; Rodríguez-Baño J
    J Antimicrob Chemother; 2015 Mar; 70(3):905-13. PubMed ID: 25344809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of tigecycline for the treatment of prolonged bacteremia due to a multiresistant VIM-1 and SHV-12 beta--lactamase-producing Klebsiella pneumoniae epidemic clone.
    Cobo J; Morosini MI; Pintado V; Tato M; Samaranch N; Baquero F; Cantón R
    Diagn Microbiol Infect Dis; 2008 Mar; 60(3):319-22. PubMed ID: 17996417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Over-treatment of carbapenemase-producing Enterobacteriaceae.
    Rihani DS; Wallace MR; Sieger BE; Waite RA; Fox M; Brown SA; Deryke CA
    Scand J Infect Dis; 2012 May; 44(5):325-9. PubMed ID: 22200121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of outcome in ICU patients with septic shock caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae.
    Falcone M; Russo A; Iacovelli A; Restuccia G; Ceccarelli G; Giordano A; Farcomeni A; Morelli A; Venditti M
    Clin Microbiol Infect; 2016 May; 22(5):444-50. PubMed ID: 26850826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tigecycline for treatment of pneumonia and empyema caused by carbapenemase-producing Klebsiella pneumoniae.
    Daly MW; Riddle DJ; Ledeboer NA; Dunne WM; Ritchie DJ
    Pharmacotherapy; 2007 Jul; 27(7):1052-7. PubMed ID: 17594211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tigecycline therapy for infections due to carbapenemase-producing Klebsiella pneumoniae in critically ill patients.
    Balandin Moreno B; Fernández Simón I; Pintado García V; Sánchez Romero I; Isidoro Fernández B; Romera Ortega MA; Alcántara Carmona S; Pérez Redondo M; Galdos Anuncibay P
    Scand J Infect Dis; 2014 Mar; 46(3):175-80. PubMed ID: 24354959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacies of colistin and tigecycline in mice with experimental pneumonia due to NDM-1-producing strains of Klebsiella pneumoniae and Escherichia coli.
    Docobo-Pérez F; Nordmann P; Domínguez-Herrera J; López-Rojas R; Smani Y; Poirel L; Pachón J
    Int J Antimicrob Agents; 2012 Mar; 39(3):251-4. PubMed ID: 22154856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Open Conversion after Aortic Endograft Infection Caused by Colistin-Resistant, Carbapenemase-Producing Klebsiella pneumoniae.
    Montelione N; Menna D; Sirignano P; Capoccia L; Mansour W; Speziale F
    Tex Heart Inst J; 2016 Oct; 43(5):453-457. PubMed ID: 27777535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of synergism between colistin, fosfomycin and tigecycline against extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolates or with carbapenem resistance.
    Ku YH; Chen CC; Lee MF; Chuang YC; Tang HJ; Yu WL
    J Microbiol Immunol Infect; 2017 Dec; 50(6):931-939. PubMed ID: 28716360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.